Xbrane Biopharma at Redeye life science day 2021 Transcript
Hello, everybody, and welcome to this webcast with the reason of us introducing two new biosimilar candidates to our portfolio and initial development of these two products. My name is Martin. I'm the CEO of an Xbrane Biopharma. I have with me, Siavash, our COO and Head of our biosimilar program. So we want to spend some time now to discuss our new portfolio and do the presentation of maybe 15, 20 minutes, or so. And then we'll have a session of Q&A.
Okay. So yes, starting with the (technical difficulty) the Capital Markets Day, which will be held in May this year (technical difficulty) quite some time to talk about similar market and what we regard to (technical difficulty) in the market and above all (technical difficulty) strong growth, which is expected in the market in coming years. On the back of multiple biological drugs (technical difficulty) and their patent protection and that being opened up distribution centers.
So one of the fastest-growing segments actually in the pharmaceutical market, we believe. It's a very good opportunity for us to tap into this market
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |